Evidence map›Paper›PMID 39066524›Full record

ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2024

Saponin Ⅰ from Shuitianqi () inhibits metastasis by negatively regulating the transforming growth factor-β1/Smad7 network and epithelial-mesenchymal transition in the intrahepatic metastasis Bagg's Albino/c mouse model.

Lyu Meixian, Zhou Huan, Zhi Limin, Zhou Jinling, Gan Rizhi, Qin Yanping, H E Nengting, Zuo Qiqi, L I Hao, Dong Min and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lyu MeixianPharmaceutical College, Guangxi Medical University, Nanning 530022, China.
Zhou HuanDepartment of Pharmacy, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530022, China.
Zhi LiminDrug clinical trial Facility office, the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530022, China.
Zhou JinlingCollege of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530022, China.
Gan RizhiDepartment of Pharmacy, the Second Affiliated Hospital of Guangxi Medical University, Nanning 530005, China.
Qin YanpingDepartment of Pharmacy, People's Hospital of Guangxi Hezhou, Hezhou 542899, China.
H E NengtingDepartment of Pharmacy, Guangzhou Women and Children's Medical Center Liuzhou Hospital, Liuzhou 545000, China.
Zuo QiqiDepartment of Pharmacy, First Affiliated Hospital of Gannan Medical University, Gannan 341000, China.
L I HaoPharmaceutical College, Guangxi Medical University, Nanning 530022, China.
Dong MinPharmaceutical College, Guangxi Medical University, Nanning 530022, China.
Liang GangPharmaceutical College, Guangxi Medical University, Nanning 530022, China.

Funding

National Natural Science Foundation of China, a New Anti-cancer Plant drug, Saponin Ⅰ from Shuitianqi (), against Invasion and Metastasis of Non-small Cell Lung Cancer and Reversing Tyrosine Kinase Inhibitors Resistance basing on Human Growth Factor/c-Mesenchymal to Epithelial Transition Factor Pathway and its Molecular Mechanism of Regulating Epithelial-Mesenchymal Transition 8164062Natural Science Foundation of Guangxi Province, Study on the Anti-hepatic Fibrosis Mechanism of Saponins from Shuitianqi () based on Transforming Growth Factor-β/Smad Signaling Pathway 2019GXNSFAA245075
6 · The paper itself

Abstract

objectiveTo examine the influence of Saponin I from Shuitianqi (

methodsThe intrahepatic metastasis Bagg's Albino/c (BALB/c) mouse model was established with human hepatocellular carcinomas (HepG2) cells, then treated with normal saline (once per day), cisplatin (2 mg/kg, once every 2 d), and SSPH Ⅰ (25, 50, and 75 mg/kg, once per day). Then, we assessed alterations in the hepatic pathology and target protein expressions in the intrahepatic metastasis BALB/c mouse model using a series of molecular biology techniques.

resultsBased on our analysis, SSPH Ⅰ significantly alleviated hepatocyte necrosis and tumor cells infiltration. Moreover, SSPH Ⅰ suppressed extracellular matrix (ECM) degradation and angiogenesis

conclusionThe SSPH Ⅰ-mediated negative regulation of the TGF-β1/Smad7 axis and EMT are critical for the inhibition of HCC invasion and metastasis.

Indexed as

Drugs, Chinese HerbalEpithelial-Mesenchymal TransitionLiver NeoplasmsSaponinsSmad7 ProteinTransforming Growth Factor beta1AnimalsCarcinoma, HepatocellularDisease Models, AnimalHep G2 CellsHumansMaleMiceNeoplasm MetastasisDrugs, Chinese HerbalSaponinsSmad7 ProteinTransforming Growth Factor beta1carcinoma, hepatocellularepithelial-mesenchymal transitionSaponin I from Shuitianqi (Rhizoma Schizocapasae Plantagineae)Smad7 proteintransforming growth factor beta1

Identifiers

PMID39066524
PMCPMC11337245

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.